Cocarboxylase

General characteristics. Structure:

Active ingredient: 50 mg of Cocarboxylasi hydrochloridum in 1 ampoule.

Excipients: sodium carbonic (sodium carbonade).

Pharmacological properties:

Pharmacodynamics. Cocarboxylase — a coenzyme of thiamin (B1 vitamin), in an organism is phosphorylated with education mono - di - and trifosforny ethers, is a part of the enzymes catalyzing a carboxylation and decarboxylation of alpha ketonic acids, pyruvic acid.

Endogenous cocarboxylase is formed in an organism of exogenous thiamin by phosphorylation, however properties of cocarboxylase not completely correspond to properties of thiamin and it cannot be used for prevention and treatment hypo - and B1 avitaminosis. Cocarboxylase improves digestion of glucose, a trophicity of fabrics of a nervous system, contributes to normalization of function of cardiovascular system.

Reduces the level of milk and pyroracemic acids in blood (increase in content of these acids leads to development of acidosis and an atsidotichesky coma).

Indications to use:

Cocarboxylase is appointed as a part of complex therapy of a liver and renal failure, a diabetic prekoma and a coma, diabetic ketoacidosis, chronic heart failure and disturbances of a cordial rhythm, peripheral neuritis.

To children drug is appointed according to the same indications. At newborns drug is used also as a part of complex therapy of the states which are followed by a hypoxia and acidosis including asphyxia of newborns, hypoxemic encephalopathy, a circulatory unefficiency, pneumonia, sepsis.

Route of administration and doses:

Cocarboxylase is entered intramusculary or intravenously (struyno or kapelno). Ampoule contents (50 mg) are dissolved just before introduction to 2 ml of water for injections. At intravenous jet administration volume is brought to 10-20 ml, at drop introduction to 200-400 ml, adding 0,9% solution of sodium of chloride or solution of a dextrose (glucose).

At disturbances of a cordial rhythm: on 100-200 mg a day within 15-30 days.

At chronic heart failure: on 50 mg in 2 hours prior to use of drugs of a foxglove 2-3 times a day.

At a diabetes mellitus (ketoacidosis, a coma) the daily dose makes 100 mg.

At an acute renal and liver failure enter intravenously struyno 100-150 mg 3 times a day or kapelno (previously having dissolved in 5% solution of a dextrose (glucose)) on 100-150 mg a day.

At peripheral neuritis appoint intramusculary in a dose 50-100 mg a day within 1-1,5 months.

To children enter intramusculary, intravenously (kapelno or struyno). Depending on weight of a state and clinical symptomatology appoint from 25 to 50 mg a day. Course of treatment from 3-7 to 15-30 days. The newborn enter intravenously (slowly) 10 mg on 1 kg of body weight once a day.

Features of use:

Use during pregnancy and during breastfeeding. Data on safety of drug at its use by pregnant women are absent. Due to the insufficient number of researches pregnant women and the feeding women should not appoint drug.

Precautionary measures at use. Without features.

Influence of drug on ability to manage vehicles and mechanisms was not studied.

Side effects:

Allergic reactions (urticaria, skin itch) are possible; at intramuscular introduction — a hyperemia, a skin itch, hypostasis (in the place of an injection).

Interaction with other medicines:

Cocarboxylase strengthens cardiological effect of cardiac glycosides and improves their portability.

Contraindications:

Hypersensitivity to drug.

Overdose:

Data on overdose are absent.

Storage conditions:

To store in the place protected from light at a temperature not above 20 °C. To store in the place, unavailable to children. A period of validity - 3 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

Lyophilisate for preparation of solution for intravenous and intramuscular administration on 50 mg in ampoules. On 10 ampoules with the application instruction, a knife ampoule or the scarificator ampoule in a pack or a box from a cardboard. On 5 ampoules with drug complete with 5 ampoules of water for injections on 2 ml with the application instruction, a knife ampoule or the scarificator ampoule in a pack or a box from a cardboard. 5 ampoules with drug and 5 ampoules with water for injections on 2 ml in separate blister strip packagings. 1 blister strip packaging with drug and 1 blister strip packaging with water for injections with the application instruction, a knife ampoule or the scarificator ampoule in a pack from a cardboard. When packaging the ampoules having a ring of a break or a point for opening the knife ampoule or the scarificator ampoule is not put.